Hysbysiad contract
Adran I:
Endid
contractio
I.1) Enw a chyfeiriad
THE UNIVERSITY OF BIRMINGHAM
RC000645
Edgbaston
BIRMINGHAM
B152TT
UK
Person cyswllt: Kseniya Samsonik
E-bost: K.Samsonik@bham.ac.uk
NUTS: UKG31
Cyfeiriad(au) rhyngrwyd
Prif gyfeiriad: https://www.birmingham.ac.uk/
I.3) Cyfathrebu
Mae'r dogfennau caffael ar gael ar gyfer mynediad uniongyrchol anghyfyngedig a llawn, yn rhad ac am ddim ar:
www.in-tendhost.co.uk/universityofbirmingham/aspx/Home
Gellir cael gwybodaeth ychwanegol o'r cyfeiriad uchod
Rhaid anfon tendrau neu geisiadau i gymryd rhan yn electronig at:
www.in-tendhost.co.uk/universityofbirmingham/aspx/Home
I.4) Y math o awdurdod contractio
Corff a lywodraethir gan gyfraith gyhoeddus
I.5) Prif weithgaredd
Addysg
Adran II: Gwrthrych
II.1) Cwmpas y caffaeliad
II.1.1) Teitl
Tender for the Supply of Services - Independent Central Review Of Primary Outcome Data For The GLO-BHNL Platform Clinical Trial - University Of Birmingham
Cyfeirnod: SC12106/23
II.1.2) Prif god CPV
85150000
II.1.3) Y math o gontract
Gwasanaethau
II.1.4) Disgrifiad byr
The University of Birmingham invites tenders for independent central review of the primary outcome data for the clinical platform trial, Glo-BNHL. The platform aims to test a wide range of therapies over its lifetime in order to find better treatments for the rare paediatric cancer, B-cell non-Hodgkin's Lymphoma. The design allows addition of new treatment arms as novel therapies become available for testing. There are currently 2 treatment arms.
Independent central review of the clinical data that informs the primary outcome measures is required, to include: cross sectional imaging by CT or MRI, PET-CT scan, bone marrow aspirate, bone marrow trephine and lumbar puncture pathology reports.
Glo-BNHL is an international trial with participating sites in the UK, Europe, USA, Canada, Australia, New Zealand and Israel. A total of 45 sites will participate, with international sites' activity coordinated by 15 National Coordinating Centres.
Glo-BNHL recently received ethics approval in the UK and will open later this year. Approval in the other participating nations will follow. An expedient solution to independent central review is therefore required.
This project may be funded by the European Regional Development Fund (ERDF) or;
- European Structural and Investment Fund (ESIF) or;
- Research Councils UK (RCUK), the strategic partnership of the UK's seven Research Councils.
Please refer to Appendix A via www.in-tendhost.co.uk/universityofbirmingham/aspx/Home for full specification of requirements.
II.1.5) Cyfanswm gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 5 000 000.00 GBP
II.1.6) Gwybodaeth am lotiau
Mae’r contract hwn wedi’i rannu’n lotiau:
Na
II.2) Disgrifiad
II.2.3) Man cyflawni
Cod NUTS:
UKG3
II.2.4) Disgrifiad o’r caffaeliad
The University of Birmingham invites tenders for independent central review of the primary outcome data for the clinical platform trial, Glo-BNHL. The platform aims to test a wide range of therapies over its lifetime in order to find better treatments for the rare paediatric cancer, B-cell non-Hodgkin's Lymphoma. The design allows addition of new treatment arms as novel therapies become available for testing. There are currently 2 treatment arms.
Independent central review of the clinical data that informs the primary outcome measures is required, to include: cross sectional imaging by CT or MRI, PET-CT scan, bone marrow aspirate, bone marrow trephine and lumbar puncture pathology reports.
Glo-BNHL is an international trial with participating sites in the UK, Europe, USA, Canada, Australia, New Zealand and Israel. A total of 45 sites will participate, with international sites' activity coordinated by 15 National Coordinating Centres.
Glo-BNHL recently received ethics approval in the UK and will open later this year. Approval in the other participating nations will follow. An expedient solution to independent central review is therefore required.
This project may be funded by the European Regional Development Fund (ERDF) or;
- European Structural and Investment Fund (ESIF) or;
- Research Councils UK (RCUK), the strategic partnership of the UK's seven Research Councils.
Please refer to Appendix A via www.in-tendhost.co.uk/universityofbirmingham/aspx/Home for full specification of requirements.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Compliance to the Specifications
/ Pwysoliad: 45
Maes prawf ansawdd: After Sales and Technical back up
/ Pwysoliad: 15
Maes prawf ansawdd: Delivery and Training
/ Pwysoliad: 15
Maes prawf ansawdd: Sustainability and Environmental
/ Pwysoliad: 10
Maes prawf ansawdd: Standard Supplier Questionnaire (SQ) Part 1 and Part 2
/ Pwysoliad: 10
Price
/ Pwysoliad:
5
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Dechrau:
30/03/2024
Diwedd:
30/03/2031
Gall y contract hwn gael ei adnewyddu: Na
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Section IV: Gweithdrefn
IV.1) Disgrifiad
IV.1.1) Y math o weithdrefn
Gweithdrefn agored
IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)
The procurement is covered by the Government Procurement Agreement:
Ydy
IV.2) Gwybodaeth weinyddol
IV.2.2) Terfyn amser i dendrau neu geisiadau i gymryd rhan ddod i law
Dyddiad:
15/12/2023
Amser lleol: 12:00
IV.2.4) Ym mha iaith/ieithoedd y gellir cyflwyno tendrau neu geisiadau i gymryd rhan
EN
IV.2.7) Amodau ar gyfer agor tendrau
Dyddiad:
15/12/2023
Amser lleol: 12:01
Section VI: Gwybodaeth ategol
VI.1) Gwybodaeth am ailddigwydd
Caffaeliad cylchol yw hwn:
Na
VI.4) Gweithdrefnau adolygu
VI.4.1) Corff adolygu
University of Birmingham
Birmingham
UK
VI.5) Dyddiad anfon yr hysbysiad hwn
15/11/2023